Ep. 43 ESMO Update: Trial Results & New Therapies in Colorectal Cancer with Dr. Jun Gong

Get caught up on the cutting edge colorectal cancer trial data from ESMO 2025 with this 30-minute BackTable Tumor Board recap! Featuring medical oncologists Dr. Jonothan Mizrahi and Dr. Jun Gong. --- SYNPOSIS The doctors discuss the DESTINY-CRC02 trial with focus on HER-2 positive metastatic colorectal cancer, the DYNAMIC-III and Pegasus studies regarding CTDNA-guided therapies, and the pivotal STELLAR-303 study for treatment-refractory microsatellite stable colorectal cancer. They also review the implications of NICHE-2 and FOxTROT studies on neoadjuvant chemotherapy versus immunotherapy for MSI high patients. Emphasis is placed on the real-world practice applications of these study findings, potential treatment shifts, and how these new trial results will impact future guidelines in colorectal cancer care. --- TIMESTAMPS 00:00 - Introduction01:25 - Overview of ESMO 2025 Annual Congress13:50 - cTDNA Monitoring in Clinical Practice16:24 - STELLAR-303 Study: Immunotherapy in MSS Colorectal Cancer20:40 - Neoadjuvant Immunotherapy for MSI High Colorectal Cancer26:39 - DESTINY-CRC02 Study: Final Analysis29:30 - Conclusion and Outro --- RESOURCES DESTINY-CRC02 Trialhttps://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00380-2/abstract DYNAMIC-III Trialhttps://www.nature.com/articles/s41591-025-04030-w STELLAR-303 Trialhttps://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)02025-2/abstract